Ketamine Therapy

Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly advancing through analytical testing and preclinical trials toward determining drug release and stability following approval by state and federal authorities....

News of psychedelics and who is using them keeps making headlines. From athletes and Silicon Valley executives to next-door neighbors, an increasing number of people are trying these substances in the hopes of getting relief from unendurable mental health conditions.  Hollywood...

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic. The deal comes on the heels of a recently announced business strategy change. What Happened: The clinic’s new proprietor, a joint venture named Awakn Via Amitis Ltd., is co-owned by...

Psychedelics biotech PharmaTher Holdings (OTCQB: PHRRF) has entered into a collaborative partnership with pharma marketing company Vitruvias Therapeutics for the commercialization of its proprietary racemic ketamine products, KETARX, in the U.S. market. The collaboration contemplates a definitive...

Closely following the announcement of what's to become of the new regulations for telehealth, including ketamine therapy, several of in-clinic treatment centers have announced they are closing their operations. One of them is the famed Field Trip Health & Wellness Ltd. (OTCMKTS:...

Research and telemedicine company Braxia Scientific Corp. (OTC: BRAXF) has filed its financial statements for the third quarter ended Dec. 31, 2022, and shared an update on its proposed acquisition by Irwin Naturals (OTCQB: IWINF). Financial results for the period show: Total revenue of $359...

Ketamine therapy provider Field Trip Health & Wellness Ltd. (OTCQB: FTHWF) shared its Q3 2023 results for three and nine months ended Dec. 31, 2022 and some of the period’s highlights. Financials: As of Dec. 31, the company held $4.9 (CA$6.7) million in cash and cash...

Lifesciences biotech company Psycheceutical Bioscience (OTC: BWVI), of which Benzinga’s advisory council member Zappy Zapolin is Chief Visionary Officer, patented a topical ketamine formulation to treat PTSD. The patent includes related methods using drug delivery technology NeuroDirect....

Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) has begun an investigative study on the dissociative effect of a proprietary and patent-pending formulation of (S)-ketamine, as well as an optimized...

Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee. New, Standardized Magic Mushroom Microdosing Capsules By Red Light Holland And Partner...

Two psychedelics companies have shared their updates and key milestones to be reached this 2023. The 5-MeO-DMT Business Clinical-stage biopharma company GH Research PLC (NASDAQ: GHRS) has received initial regulatory and ethical approvals to commence a multi-site Phase 2b trial for its lead product...

Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression (TRD.). The company stated that while the...

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed: Revenue of $314.827 (CA$430,504) via Awakn's European clinics, compared to $Nil in the prior year. That's...

Ketamine-therapy provider Revitalist Lifestyle & Wellness Ltd. (OTCQB: RVLWF) along with psilocybin biotech company WAKE Network Inc. announced a joint venture partnership to open psychedelic clinics and retreats with vertical offerings and a personalized medicine and therapy...

Revitalist Increases Patient Access By Financing Costs With M-Lend Financial Ketamine clinics operator Revitalist Lifestyle and Wellness Ltd. (OTCQB: RVLWF) has partnered with US financing company M-Lend Financial to offer patients a loan for up to $100,000 covering services related to ketamine and...